The risk of delisting grows as clinical investment increases

Seventeen biotech firms lose pre-tax loss grace period

Editor's Note
In the first half of this year, Korean biotech companies have consecutively secured technology export contracts worth trillions of won with global big pharma firms, fueling optimism across the industry. However, a closer examination of these deals reveals a reality that differs from what appears on the surface. Notably, the payments received by Korean companies are significantly lower than those received by Chinese firms from big pharma, even for similar promising technologies. Bio-technology is regarded as a key strategic asset for the nation’s future. Therefore, it is crucial to understand where the gap with China—a country striving to leap from a competitor to a global leader—originates. The Asia Business Daily sheds light on this reality and explores its underlying factors and possible solutions.

① Despite Similar Promising Technologies, Upfront Payments Are a Third of China’s


② Korea Sells at Phase 1, China Advances to Phase 3


③ Delisting After Raising Funds for Clinical Trials... The Double Whammy Squeezing K-Bio


④ Accelerating Clinical Trials and Easing Delisting Regulations Are Needed to Close the Gap


There is a growing consensus that the reason Korean biotechs are compelled to out-license drug candidates at early clinical stages lies in the limitations of the domestic capital market. The cost of new drug clinical trials rises steeply as they progress through each phase. For biotechs, the only option is to invest despite incurring losses, but if this situation continues, they are likely to be designated as “watchlist” stocks under capital market regulations. This structural contradiction—where bold investment in clinical trials increases the risk of being delisted—means that companies are repeatedly forced to sell their technology at “bargain” prices to mitigate such risks.


Recently, the pre-tax loss from continuing operations (so-called “Bopchasun”) requirement for KOSDAQ-listed companies has emerged as the most contentious regulatory issue. The industry is calling for relaxation of this rule, considering the unique nature of new drug companies, but the authorities are steadfast in their stance that swift removal of unsound companies is essential to restore market trust. These opposing views are in direct conflict.

[KR-China Biotech Divergence] ③Raising Funds for Clinical Trials Leads to Delisting... The Double Bind Tightening K-Bio View original image

The trend is actually leaning towards stricter regulations. According to financial authorities and the investment market as of June 16, the Financial Services Commission and Korea Exchange have been gradually raising the listing maintenance standards for KOSDAQ-listed companies in line with the delisting system reform plan announced last year. The market capitalization requirement will rise from 4 billion won to 20 billion won in July 2024, and to 30 billion won in 2027. The sales requirement will also be increased from 3 billion won to 10 billion won. The exchange has even established a dedicated delisting management team focused on removing unsound companies and is operating a concentrated management period through July 2024. As a result, 16 pharmaceutical and biotech companies with market capitalizations below 30 billion won are now within the scope of potential delisting.

The Burden of Pre-tax Losses Grows with Increased Investment in Clinical Trials

The biggest destabilizing factor for new drug companies is the pre-tax loss. The exchange designates KOSDAQ-listed companies as watchlist stocks if they record pre-tax losses exceeding 50% of equity capital more than twice in the past three fiscal years (with each instance exceeding 1 billion won). For new drug companies listed via the technology-special listing track, this requirement is waived for three fiscal years (including the year of listing), but the same standards as general listed companies apply thereafter. As clinical trial expenses accumulate losses, equity capital decreases, causing the pre-tax loss ratio to soar. This puts companies at greater risk of being designated as watchlist stocks just when they need to make substantial investments in late-stage clinical trials.


According to the Financial Supervisory Service, as of the 2024 fiscal year settlement, nine bio companies have newly been put on the watchlist, with more than five of them due to pre-tax loss. As the grace period for technology-special listings from the investment boom of 2020 ends en masse, 17 biotech companies listed under this track have had their pre-tax loss grace period expire since 2023.

[KR-China Biotech Divergence] ③Raising Funds for Clinical Trials Leads to Delisting... The Double Bind Tightening K-Bio View original image

There are also increasing cases of companies running out of funds after directly attempting late-stage clinical trials. Bridge Biotherapeutics, which had previously received domestic innovative pharmaceutical certification, faced a funding crisis while conducting global Phase 2 clinical trials with its own capital. The company raised 54.6 billion won through two third-party paid-in capital increases in 2022 and an additional 24.1 billion won through a shareholder-allotted paid-in capital increase in 2024, but its pre-tax loss ratio to equity was 80.4% in 2022, 215.2% in 2023, and 72.3% in 2024—repeatedly exceeding the criteria. As a result, it was designated as a watchlist stock in March last year. Ultimately, in June last year, the company handed over management control to U.S. virtual asset management firm Parataxis, receiving a 25 billion won capital injection that resolved the pre-tax loss issue, but the founder had to give up ownership of the company.


For companies listed via the technology-special track, remaining on the watchlist is also triggered if annual sales stay below 3 billion won for a set period. Even AbClon, which succeeded in out-licensing an antibody drug at the global Phase 3 clinical stage, was designated a watchlist stock in March last year after its 2024 sales came in at only 2.3 billion won. After the upfront payment from the licensing deal was reflected, sales rose to 4.7 billion won and the company was removed from the watchlist in March this year, but this case highlighted how applying sales-based criteria unrelated to new drug development can impact companies at advanced clinical stages. It is a double bind: spending for clinical trials leads to pre-tax loss, and insufficient sales lead to sales-based listing requirements. A biotech industry insider commented, “Some companies even resort to acquiring bakery businesses or similar revenue-generating firms to meet the criteria—a distorted survival strategy.”

China Advances to Phase 3, While Korea Worries About Maintaining Its Listing

This structural issue is cited as a core factor widening the gap between Korea and China. Chinese biotechs build negotiating power by accumulating late-stage clinical data with their own funds and rapid clinical progress, whereas Korean companies must worry about maintaining their listing status even before raising funds for late-stage trials. An industry source stated, “New drug development is an industry that requires massive capital over more than a decade with little to no sales, yet listing status in Korea hinges on loss ratios. The more companies focus on clinical trials, the closer they get to being delisted.”



While listing maintenance criteria such as equity capital and market capitalization exist on the U.S. NASDAQ, Hong Kong GEM, and Japan’s Tokyo Stock Exchange Growth Market, regulations that designate companies as watchlist stocks solely based on loss ratios—like in Korea—are either extremely weak or nonexistent. Some experts estimate that if the same pre-tax loss criteria were applied on NASDAQ, 30% of all listed companies would be on the watchlist.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing